Pyruvate kinase M2: A key enzyme of the tumor metabolome and its medical relevance

Biomedical Research

Volumn 23, Issue SPEC. ISSUE, 2012, Pages 133-142

  Mazurek, Sybille ^a,b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b ScheBo Biotech AG   (Germany)

Author keywords

CRC; Fecal M2 PK; Glycolysis; M2 PK; PKM2; Pyruvate kinase M2; Tumor diagnosis; Tumor therapy

Indexed keywords

A 77 1726; ANTINEOPLASTIC AGENT; CISPLATIN; DIMER; FLUOROURACIL; ONCOPROTEIN; PYRUVATE KINASE; PYRUVATE KINASE M2; SHIKONIN; TERIFLUNOMIDE; TETRAMER; TUMOR ENDOTHELIAL MARKER 8 IMMUNOGLOBULIN FC FRAGMENT; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER SCREENING; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; COLORECTAL CANCER; DIMERIZATION; DISEASE MARKER; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FOLLOW UP; GLYCOLYSIS; HUMAN; METABOLOMICS; NONHUMAN; POINT OF CARE TESTING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN QUATERNARY STRUCTURE; SENSITIVITY AND SPECIFICITY;

EID: 84857171789     PISSN: 0970938X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Eigenbrodt E, Glossmann H. Glycolysis - one of the keys to cancer? Trends Pharmacol Sci 1980; 1: 240-245.
2. Warburg O, Poesener K, Negelein E. Über den Stoffwechsel der Tumoren. Biochem Z 1924;152: 319-344.
3. Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol 2011; 43: 969-980.
4. Takenaka M, Yamada K, Lu T, Kang R, Tanaka T, Noguchi T. Alternative splicing of the pyruvate kinase M gene in a minigene system. Eur J Biochem 1996; 235: 366-371.
5. Dombrauckas JD, Santarsiero BD, Mesecar AD. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 2005; 44: 9417-9429.
6. Sun Q, Chen X, Ma J, Peng H, Wang F, Zha X, Wang Y, Jing Y, Yang H, Chen R, Chang L, Zhang Y, Goto J, Onda H, Chen T, Wang MR, Lu Y, You H, Kwiatkowski D, Zhang H. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci USA 2011, 108: 4129-4134.
7. Akhtar K, Gupta V, Koul A, Alam N, Bhat R, Bamezai RNK. Differential behavior of missense mutations in the intersubunit contact domain of the human pyruvate kinase M2 isozyme. J Biol Chem 2009; 284: 11971-11981.
8. Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, Lythgoe K, Dong S, Lonial S, Wang X, Chen GZ, Xie J, Gu TL, Polakiewicz RD, Roesel JL, Boggon TJ, Khuri FR, Gilliland DG, Cantley LC, Kaufman J, Chen J. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal 2009; 2: ra73.
9. Bonucelli G, Whitaker-Menezes D, Castello-Cros R, Pavlides S, Pestell RG, Fatatis A, Witkiewicz AK, Vander Heiden MG, Migneco G, Chiavarina B, Frank PG, Capozza F, Flomenberg N, Martinez-Outschoorn U, Sotgia F, Lisanti MP. Glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts. Cell Cycle 2010; 9: 1960-1971.
10. Diaz-Jullien C, Moreira D, Sarandeses CS, Covelo G, Barbeito P, Freire M. The M2-type isoenzyme of pyruvate kinase phosphorylates prothymosin a in proliferating lymphocytes. Biochim Biophys Acta 2011; 1814: 355-365.
11. Luo W, Hu H, Chang R, Zhong J, Knabel M, OMeally R, Cole RN, Pandey A, Semenza GL. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxiainducible factor 1. Cell 2011; 145: 732-744.
12. Lee J, Kim HK, Han YM, Kim J. Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription. Int J Biochem Cell Biol 2008; 40: 1043-1054.
13. Ignacak J, Stachurska MB. The dual activity of pyruvate kinase type M2 from chromatin extracts of neoplastic cells. Comp Biochem Physiol Part B 2003; 134: 425-433.
14. Stetak A, Veress R, Ovádi J, Csermely P, Kéri G, Ullrich A. Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. Cancer Res 2007; 67: 1602-1808.
15. Zhang Z, Liu Q, Che Y, Yuan X, Dai L, Zeng B, Jiao G, Zhang Y, Wu X, Yu Y, Zhang Y, Yang R. Antigen presentation by dendritic cells in tumors is disrupted by altered metabolism that involves pyruvate kinase M2 and its interaction with SOCS3. Cancer Res 2010; 70: 89-98.
16. Spoden GA, Rostek U, Lechner S, Mitterberger M, Mazurek S, Zwerschke W. Pyruvate kinase isoenzyme M2 is a glycolytic sensor differentially regulating cell proliferation, cell size and apoptotic cell death dependent on glucose supply. Exp Cell Res 2009; 315: 2765-2774.
17. Muellner S, Stark H, Niskanen P, Eigenbrodt E, Mazurek S, Fasold H. From target to lead synthesis. In: Proteomics in Drug Research. Wiley-VCH, Weinheim 2006; 28: pp 187-207.
18. Vander Heiden MG, Christofk HR, Schuman E, Subtelny AO, Sharfi H, Harlow EE, Xian J, Cantley LC. Identification of small molecule inhibitors of pyruvate kinase M2. Biochem Pharmacol 2010; 79: 1118-1124.
19. Chen J, Xie J, Jiang Z, Wang B, Wang Y, Hu X. Shikonin and ist analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase - M2. Oncogene 2011; 30: 4297-4306.
20. Boxer MB, Jiang J-K, VanderHeiden MG, Shen M, Skoumbourdis AP, Southall N, Veith H, Leister W, Austin CP, Park HW, Inglese J, Cantley LC, Auld DS, Thomas CJ. Evaluation of substituted N,N ́-Diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. J. Med Chem 2010; 53: 1048-1055.
21. Jiang JK, Boxer MB, Vander Heiden MG, Shen M, Skoumbourdis AP, Southall N, Veith H, Leister W, Austin CP, Park HW, Inglese J, Cantley LC, Auld DS, Thomas CJ. Evaluation of Thieno[3,2- b]pyrrole[pyridazinones as activators of the tumor cell specific M2 isoeform of pyruvate kinase. Bioorg Med Chem Lett 2010; 20: 3387-3393.
22. Guo W, Zhang Y, Chen T, Wang Y, Xue J, Zhang Y, Xiao W, Mo X, Lu Y. Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model. J Cancer Res Clin Oncol 2011; 137: 65-72.
23. Shi HS, Li D, Zhang J, Wang YS, Yang L, Zhang HL, Wang XH, Mu B, Wang W, Ma Y, Guo FC, Wei YQ. Silencing of PKM2 increases the efficacy of docetaxel in human lung cancer xenografts in mice. Cancer Sci 2010; 101: 1447-1453.
24. Duan HF, Hu XW, Chen JL, Gao LH, Xi YY, Lu Y, Li JF, Zhao SR, Xu JJ, Chen HP, Wu CT. Antitumor activities of TEM8-Fc: An engineered antibody-like molecule targeting tumor endothelial marker 8. J Natl Cancer Inst 2007; 99: 1551-1555.
25. Yoo BC, Ku JL, Hong SH, Shin YK, Park SY, Kim HK, et al. Decreased pyruvate kinase M2 activity linked to cisplatin resistance in human gastric carcinoma cell lines. Int J Cancer 2004; 108: 532-539.
26. Li SL, Ye F, Cai WJ, Hu HD, Hu P, Ren H, Zhu FF, Zhang DZ. Quantitative proteome analysis of multidrug resistance in human ovarin cancer cell line. J Cell Biochem 2010; 109: 625-633.
27. Martinez-Balibrea E, Plasencia C, Ginés A, Martinez Cardús A, Musulén E, Aquilera R, Manzano JL, Neamati N, Abad A. A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines. Mol Cancer Ther 2009; 8: 771-778.
28. Shin YK, Yoo BC, Hong YS, Chang HJ, Jung KH, Jeong SY, Park JG. Upregulation of glycolytic enzymes in proteins secreted from human colon cancer cells with 5-fluorouracil resistance. Electrophoresis 2009; 30: 2182-2192.
29. Wechsel HW, Petri E, Bichler KH, Feil G. Marker for renal cell carcinoma (RCC): The dimeric form of pyruvate kinase type M2 (Tu M2-PK). Anticancer Res 1999; 19: 2583-2590.
30. Ugurel S, Bell N, Sucker A, Zimpfer A, Rittgen W, Schadendorf D. Tumor type M2 pyruvate kinase (TuM2-PK) as novel plasma tumor marker. Int J Cancer 2005; 117: 825-830.
31. Schneider J, Neu K, Grimm H, Velcovsky HG, Weisse G, Eigenbrodt E. Tumor M2-pyruvate kinase in lung cancer patients: Immunohistochemical detection and disease monitoring. Anticancer Res 2002; 22: 311-318.
32. Lüftner D, Mesterharm J, Akrivakis C, Geppert R, Petrides PE, Wernecke KD, Possinger, K. Tumor M2- pyruvate kinase expression in advanced breast cancer. Anticancer Res 2000; 20: 5077-5082.
33. Kaura B, Bagga R, Patel FD. Evaluation of the pyruvate kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma. J Obstet Gynaecol Res 2004; 30: 193-196.
34. Ahmed AS, Dew T, Lawton FG, Papadopoulos AJ, Devaja O, Raju KS, Sherwood RA. M2-PK as a novel marker in ovarian cancer: A prospective cohort study. Eur J Gynaec Oncol 2007; 28: 83-88.
35. Kumar Y, Tapuria N, Kirmani N, Davidson BR. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker. Eur J Gastroenterol Hepatol 2007; 19: 265-276.
36. Elia S, Massoud R, Guggino G, Cristino B, Cortese C, De Massimi AR, Zenobi R. Tumor type M2-pyruvate kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures. Eur J Cardiothorac Surg 2008; 33: 723-727.
37. Mazurek S. New molecular markers: M2-PK. WEO/OMED Colorectal Cancer Screening Committee Meeting, DDW 2011, Chicago,IL.
38. Ahlquist DA. Molecular detection of colorectal neoplasia. Gastroenterology 2010; 138: 2127-2139.
39. Ryu H, Walker JK, Kim S, Koo N, Barak LS, Noguchi T, Kang BY, Kim KM. Regulation of M2-type pyruvate kinase mediated by the high-affinity IgE receptors is required for mast cell degranulation. Brit J Pharmacol 2008; 154: 1035-1046.
40. Koo N, Kim KM. Distinct effects on M2-type pyruvate kinase are involved in the demethylsulfoxide-induced modulation of cellular proliferation and degranulation of mast cells. Arch Pharm Res 2009; 32: 1637-1642.
41. Venkatesan A, Uzasci L, Chen Z, Rajbhandari L, Anderson C, Lee MH, Bianchet MA, Cotter R, Song H, Nath A. Impairment of adult hippocampal neural progenitor proliferation by methamphetamine: role for nitrotyrosination. Molecular Brain 2001; 4: 28-42.
42. Hardt PD, Mazurek S, Toepler M, Schlierbach P, Bretzel RG, Eigenbrodt E, Kloer HU. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer 2004; 91: 980-984.
43. Naumann M, Schaum B, Oremek GM, Hanisch E, Rösch W, Mössner J, Caspary WF, Stein J. Faecal pyruvate kinase type M2 - a valid screening parameter for colorectal cancer? Preliminary results from a multicentre comparative study. Dtsch Med Wochenschr 2004; 129: 1806-1807.
44. Kloer HU, Hardt PD Schlierbach P, Toepler M. The tumour metabolic marker M2-PK in stool: a new biomarker for colorectal cancer. Abstract from ASCO Meeting 2005, Orlando, Fl.
45. McLoughlin R, Shiel E, Sebastian S, ÓConnor RB, ÓMorain C. Tumour M2-PK, a novel screening tool for colorectal cancer. Abstract from the NCRI Conference 2005, Birmingham, UK.
46. Vogel T, Driemel C, Hauser A, Hansmann A, Lange S, Jonas M, Möslein G. Comparison of different stool tests for the detection of cancer of the colon. Dtsch Med Wochenschr 2005; 130: 872-877.
47. Shastri YM, Naumann M, Oremek GM, Hanisch E, Rösch W, Mössner J, Caspary WF, Stein JM. Prospective multicenter evaluation of faecal tumour pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia. Int J Cancer 2006; 119: 2651-2656.
48. Tonus C, Neupert G, Sellinger M. Colorectal cancer screening by non-invasive metabolic biomarker fecal M2-PK. World J Gastroenterol 2006; 12: 7007-7011.
49. Mulder SA, van Leerdam ME, van Vuuren AJ, Francke J, van Toorenenbergen AW, Kuipers EJ, Ouwendijk RJ. Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer. Eur J Gastroenterol Hepatol 2007; 19: 878-882.
50. Haug U, Rothenbacher D, Wente MN, Seiler CM, Stegmaier C, Brenner H. Tumour M2-PK as a stool marker for colorectal cancer: comparative analysis in a large sample of unselected older adults vs colorectal cancer patients. Br J Cancer 2007; 96: 1329-1334.
51. Koss K, Maxton D, Jankowski JA. Faecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumour staging and surgical intervention. Colorectal Dis 2008; 10: 244-248.
52. Shastri YM, Loitsch S, Hoepffner N, Povse N, Hanisch E, Rösch W, Mössner J, Stein JM. Comparison of an established simple office-based immunological FOBT with faecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study. Am J Gastroenterol 2008; 103: 1496-1504.
53. Schmidt C. Wertigkeit der fäkalen Tumour M2 Pyruvate kinase (TuM2-PK) für die Detektion eines kolorektalen Karzinoms. Doctoral thesis of the Medical Faculty of the University of Würzburg, 2009.
54. Haug U, Hundt S, Brenner H. Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study. Br J Cancer 2008; 99: 133-135.
55. Bellutti M, Mönkemüller K, Malfertheiner R. Faecal Tumour M2-pyruvate kinase (M2-PK) as a potential screening parameter for colorectal adenoma and carcinoma: preliminary results. Abstract Eur Bridging Meeting 2005, Magdeburg, Germany.
56. Tonus C, Neupert G, Witzel K. The faecal tumour M2-PK screening test for invasive & pre-invasive colorectal cancer: estimated specificity & results as a function of age for a study population of 4854 volunteers. Nowotwory J Oncol 2009, 59: 32e-37e.
57. Ewald N, Schaller M, Bayer M, Akinci A, Bretzel RG, Kloer HA, Hardt PD. Fecal pyruvate kinase M2 (tumor M2-PK) measurement: a new screening concept for colorectal cancer. Anticancer Res 2007; 27: 1949-1952.